
October 5, 2021

BSE Limited

1st Floor, P J Towers,
Dalal Street,
Mumbai-400001

Code: 532321

National Stock Exchange of India Limited

Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra-Kurla Complex, Bandra (East),
Mumbai-400051

Code: Cadilahc

Re.: Clarification with regard to media report

Ref.: Emails of the stock exchanges, both dated October 4, 2021

Dear Sir / Madam,

With reference to the emails of the stock exchanges, both dated October 4, 2021, asking us to provide information on the news item regarding "Zydus Cadila gets permission to conduct phase III trial for two-dose Covid vaccine", we hereby confirm that we have got the permission for conduct of phase III trials for two-dose Covid vaccine.

We generally report all milestone events related to Covid vaccine, which can be price sensitive information. In this case, since we have already got emergency use authorisation for three-dose vaccine earlier (which is already informed to the stock exchanges vide our letter dated August 20 2021), we thought that giving information on completion of phase-III trials, when we apply for authorisation from the government would be right time for intimating to stock exchanges.

Thanking you,

Yours faithfully,

For, **CADILA HEALTHCARE LIMITED**

DHAVAL N. SONI
COMPANY SECRETARY